(S1 (S (S (NP (JJ Oxidative) (NN DNA) (NN damage)) (VP (VBZ correlates) (PP (IN with) (NP (NP (NN cell) (NN immortalization)) (CC and) (NP (NN N1ENTITY) (NN expression)))) (PP (IN in) (NP (JJ hepatocellular) (NN carcinoma))))) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (S (NP (NN MicroRNAs) (NN expression)) (VP (VBZ has) (VP (VBN been) (ADVP (RB extensively)) (VP (VBN studied) (PP (IN in) (NP (JJ hepatocellular) (NN carcinoma))))))) (CC but) (S (NP (JJ little)) (VP (VBZ is) (VP (VBN known) (S (VP (VBG regarding) (NP (DT the) (NN relationship)))) (, ,) (SBAR (IN if) (FRAG (DT any))) (, ,) (PP (IN with) (NP (NP (NN inflammation)) (, ,) (NP (NP (NN production)) (PP (IN of) (NP (NP (JJ reactive) (NN oxygen) (NNS species)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-))))) (, ,) (NP (NN host) (POS ') (NN s) (NN repair) (NNS mechanisms)) (CC and) (NP (NN cell) (NN immortalization)))))))) (. .))))
(S1 (S (NP (DT This) (NN study)) (VP (VBD aimed) (PP (PP (IN at) (S (VP (VBG assessing) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (JJ oxidative) (NN DNA) (NN damage)) (PRN (-LRB- -LRB-) (NP (NN 8-hydroxydeoxyguanosine-8-OHdG)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (JJ different) (NNS phases)) (PP (IN of) (NP (DT the) (JJ carcinogenetic) (NN process)))))) (, ,) (PP (IN in) (NP (NP (NN relation)) (PP (TO to) (NP (NN DNA) (NN repair) (NN gene) (NN polymorphism))))) (, ,) (NP (JJ telomeric) (NN dysfunction))))) (CC and) (PP (TO to) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ several) (NNS microRNAs)) (, ,) (NP (NP (JJ non-coding) (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (NP (JJ post-transcriptional) (NN regulation)) (, ,) (NP (NN cell) (NN proliferation)) (, ,) (NP (NN differentiation)) (CC and) (NP (NN death)))))))))))) (. .)))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (NP (NN Tissue) (NNS samples)) (VP (VBN obtained) (PP (CC either) (PP (IN at) (NP (NN surgery))) (, ,) (NP (NP (NP (JJ -LSB-neoplastic)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ adjacent) (JJ non-cancerous) (JJ cirrhotic) (NNS tissues)) (PRN (-LRB- -LRB-) (NP (NN NCCT)) (-RRB- -RRB-))) (-RRB- -RSB-))) (PP (IN at) (NP (NP (NN percutaneous)) (CC or) (NP (JJ laparoscopic) (NN biopsy)))) (PRN (-LRB- -LRB-) (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NN HCV) (CC or) (JJ HBV-related) (NN hepatitis)))) (CC or) (NP (NP (NNS patients)) (VP (VBG undergoing) (NP (NN cholecystectomy))))) (-RRB- -RRB-)))) (VP (VBD were) (VP (VBN analysed) (PP (IN for) (NP (NP (NP (NN 8-OHdG)) (PRN (-LRB- -LRB-) (NP (JJ HPLC-ED)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NP (NN N40ENTITY)) (PRN (-LRB- -LRB-) (NP (DT a) (NN DNA) (NN repair) (NN gene)) (-RRB- -RRB-))) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN PCR-RFLP)) (-RRB- -RRB-))) (, ,) (NP (NN N38ENTITY) (NN activity)) (, ,) (NP (NP (NN telomere) (NN length)) (PRN (-LRB- -LRB-) (NP (NN T/S)) (, ,) (PP (IN by) (NP (NN RT-PCR))) (-RRB- -RRB-))) (, ,) (NP (NN Taqman) (NN microRNA) (NN assay)) (CC and) (NP (NP (NN N39ENTITY/N36ENTITY) (NN mRNA)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-)))))))) (. .))))
(S1 (S (S (NP (NP (NP (CD Fifty-eight) (NNS samples)) (PP (IN from) (NP (CD 29) (NN HCC) (NNS patients))) (-LRB- -LRB-) (VP (VBN obtained) (PP (IN in) (NP (DT both) (JJ neoplastic) (CC and) (JJ peritumoral) (NNS tissues)))) (-RRB- -RRB-)) (, ,) (NP (NP (NP (CD 22)) (PP (IN from) (NP (JJ chronic) (NN hepatitis)))) (PRN (-LRB- -LRB-) (NP (NN CH)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 10) (NNS controls)) (PRN (-LRB- -LRB-) (NP (NN cholecystectomy) (NN patients-CON)) (-RRB- -RRB-)))) (VP (VBD were) (VP (VBN examined)))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NN Eight-OHdG) (NNS levels)) (VP (VBD were) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NP (NN HCC)) (CC and) (NP (NN NCCT)))) (PP (IN than) (PP (IN in) (NP (NP (NN CH)) (CC and) (NP (NN CON)))))) (PRN (-LRB- -LRB-) (S (NP (NN p)) (VP (JJ =) (NP (CD 0.001)))) (-RRB- -RRB-)))) (. .))))
(S1 (S (S (NP (NN N37ENTITY) (NN activity)) (VP (VBD was) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NN HCC))) (PP (IN than) (PP (IN in) (NP (DT the) (VBG remaining) (NNS subgroups)))) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.002)) (-RRB- -RRB-))))) (: ;) (S (ADVP (RB conversely)) (NP (NN T/S)) (VP (VBD was) (ADJP (RB significantly) (JJR lower)) (PP (IN in) (NP (NP (NN HCC)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.05)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NN N2ENTITY)) (VP (VBD were) (VP (VBN down-regulated) (PP (IN in) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NNS HCCs))))) (SBAR (IN while) (S (NP (NN N3ENTITY)) (VP (VBD was) (VP (VBN up-regulated)))))))) (. .)))
(S1 (S (S (NP (DT A) (JJ positive) (NN correlation)) (VP (VBD was) (VP (VBN observed) (PP (IN among) (NP (NP (NN 8-OHdG) (NNS levels)) (, ,) (NP (NN disease) (NN stage)) (, ,) (NP (NN N35ENTITY) (NN activity)) (, ,) (NP (NN N32ENTITY)) (CC and) (NP (NN N33ENTITY/N21ENTITY) (NNS levels))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN HCC))) (, ,) (NP (NN N4ENTITY) (NN expression)) (VP (VBD correlated) (ADVP (RB positively)) (PP (IN with) (NP (NP (NN N22ENTITY) (NN activity)) (, ,) (NP (NN 8-OHdG) (NNS levels)) (CC and) (NP (NN N23ENTITY/N24ENTITY) (NN mRNA)))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (DT The) (JJ above) (NNS findings)) (VP (VP (VBP confirm) (NP (NP (DT the) (NN accumulation)) (, ,) (PP (IN in) (NP (NP (DT the) (NN progression)) (PP (IN of) (NP (JJ chronic) (NN liver) (NN damage))) (PP (TO to) (NP (NN HCC))))) (, ,) (PP (IN of) (NP (DT a) (JJ ROS-mediated) (JJ oxidative) (NN DNA) (NN damage))))) (, ,) (CC and) (VP (VBP suggest) (SBAR (IN that) (S (NP (DT this)) (VP (VBZ correlates) (PP (PP (IN with) (NP (NP (NN induction)) (PP (IN of) (NP (NN N17ENTITY) (NN activity))))) (CC and) (, ,) (PP (IN as) (NP (DT a) (JJ novel) (NN finding))) (, ,) (PP (IN with) (NP (NP (NN over-expression)) (PP (IN of) (NP (NP (NN N5ENTITY)) (, ,) (NP (NP (DT a) (NN microRNA)) (SBAR (WHNP (WDT that)) (S (VP (VBZ plays) (NP (DT a) (NN role)) (PP (PP (IN in) (NP (PDT both) (DT the) (JJ apoptotic) (NN process))) (CC and) (PP (IN in) (NP (JJ cellular) (NN proliferation) (NNS pathways))))))))))))))))))) (. .))))
(S1 (S (S (NP (JJ MYCN-regulated) (NN N6ENTITY)) (VP (VBZ inhibits) (NP (NP (NN secretion)) (PP (IN of) (NP (NP (DT the) (NN tumor) (NN N19ENTITY)) (PRN (-LRB- -LRB-) (NP (NN N20ENTITY)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN neuroblastoma)))))) (. .)))
(S1 (S (S (NP (DT The) (NN N30ENTITY)) (VP (VBZ is) (ADVP (RB frequently)) (VP (VBN amplified) (PP (IN in) (NP (NN neuroblastoma)))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (ADJP (RBS most) (JJ consistent)) (NNS markers)) (PP (IN of) (NP (NN bad) (NN prognosis))) (PP (IN for) (NP (DT this) (NN disease)))))))) (. .)))
(S1 (S (S (NP (NP (NN N31ENTITY)) (PRN (-LRB- -LRB-) (NP (NN N44ENTITY)) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (VBN secreted) (NN protein)) (PP (IN of) (NP (NP (DT the) (NN N43ENTITY)) (PP (IN of) (NP (NN N46ENTITY) (NNS regulators)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ functions) (PP (IN as) (NP (DT a) (NN tumor) (NN suppressor))) (PP (IN in) (NP (NP (DT a) (NN range)) (PP (IN of) (NP (NP (NNS cancers)) (, ,) (PP (VBG including) (NP (NN neuroblastoma))))))))) (. .)))
(S1 (S (S (NP (NN MYCN)) (VP (VBD was) (ADVP (RB recently)) (VP (VBN found) (S (VP (TO to) (VP (VB downregulate) (NP (NN N45ENTITY)))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (JJ MYCN) (NN knockdown)) (PP (IN in) (NP (ADJP (ADJP (JJ MYCN-amplified)) (PRN (-LRB- -LRB-) (NP (NN MNA)) (-RRB- -RRB-))) (NN neuroblastoma) (NN cell) (NNS lines)))) (VP (VBZ increases) (NP (NP (NN secretion)) (PP (IN of) (NP (JJ endogenous) (NN N48ENTITY))) (PP (TO to) (NP (DT the) (NN culture) (NNS media))))))))) (. .)))
(S1 (S (S (NP (NP (NNS MicroRNAs)) (PRN (-LRB- -LRB-) (NP (NN miRNAs)) (-RRB- -RRB-))) (VP (VBP are) (NP (NP (ADJP (NP (QP (RB approximately) (CD 20)) (NN nt)) (JJ long)) (JJ single-stranded) (NN RNA) (NNS molecules)) (SBAR (WHNP (WDT that)) (S (VP (VBP downregulate) (NP (NN messenger) (NNS RNAs)) (PP (IN by) (S (VP (VBG targeting) (NP (NP (DT the) (CD 3) (`` ') (JJ untranslated) (NN region)) (PRN (-LRB- -LRB-) (NP (CD 3) (`` ') (NN UTR)) (-RRB- -RRB-)))))))))))) (. .)))
(S1 (S (S (NP (JJ Many) (NNS miRNAs)) (VP (VP (VBP regulate) (NP (NP (NNS genes)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN pathogenesis)) (PP (IN of) (NP (NN cancer)))))))) (CC and) (VP (VBP are) (ADVP (RB extensively)) (VP (VBN deregulated) (PP (IN in) (NP (JJ different) (NNS tumors))))))) (. .)))
(S1 (S (S (VP (VBG Using) (NP (NN miRNA) (NN target) (NN prediction) (NN software)))) (, ,) (NP (PRP we)) (VP (VBD found) (NP (NP (JJ several) (JJ MYCN-regulated) (NNS miRNAs)) (SBAR (WHNP (WDT that)) (S (VP (MD could) (VP (VB target) (NP (NP (DT the) (CD 3) (`` ') (NN UTR) (NN sequence)) (PP (IN of) (NP (NN N47ENTITY)))))))) (, ,) (PP (VBG including) (NP (NP (NNP N7ENTITY)) (, ,) (NP (NNP N8ENTITY)) (CC and) (NP (NNP N9ENTITY)))))) (. .)))
(S1 (S (S (NP (NP (NN N42ENTITY) (NN expression)) (PP (IN from) (NP (NP (DT a) (NN reporter) (NN vector)) (VP (VBG containing) (NP (DT the) (NN N41ENTITY)))))) (VP (VBD was) (VP (VBN decreased) (SBAR (WHADVP (WRB when)) (S (NP (DT this) (NN construct)) (VP (VBD was) (VP (VBN cotransfected) (PP (IN with) (NP (NP (NP (NNP N10ENTITY)) (, ,) (NP (NNP N11ENTITY)) (CC or) (NP (NNP N12ENTITY))) (PP (IN in) (NP (NN HEK293) (NNS cells)))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Mutation)) (PP (IN of) (NP (DT the) (NN N13ENTITY) (JJ seed) (NN sequence))) (PP (IN in) (NP (DT the) (CD 3) (POS ') (NN UTR)))) (ADVP (RB completely)) (VP (VBD rescued) (NP (NP (DT the) (VBN observed) (NN decrease)) (PP (IN in) (NP (NN reporter) (NN expression)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN cotransfected) (PP (IN with) (NP (NP (NN N14ENTITY)) (CC and) (NP (NN N15ENTITY))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Antagomir)) (CC and) (NP (JJ miRNA-mimic) (NNS transfections))) (PP (IN in) (NP (NN neuroblastoma) (NN cell) (NNS lines)))) (VP (VBD confirmed) (SBAR (IN that) (S (NP (NP (NN N27ENTITY) (NN secretion)) (PP (TO to) (NP (DT the) (NN culture) (NNS media)))) (VP (VBZ is) (VP (VBN regulated) (PP (IN by) (NP (NN N16ENTITY))))))))) (. .)))
(S1 (S (S (ADJP (JJ Consistent) (PP (IN with) (NP (NP (NNS reports)) (PP (IN from) (NP (JJ other) (NNS cancers))))))) (, ,) (NP (PRP we)) (VP (VBD found) (NP (NN N25ENTITY)) (S (VP (VP (TO to) (VP (VB be) (VP (VBN expressed) (PP (IN in) (NP (NP (DT the) (NN endothelium)) (PP (IN of) (NP (JJ primary) (NN neuroblastoma) (NNS samples)))))))) (CC and) (VP (TO to) (VP (VB be) (ADJP (JJ absent) (PP (IN in) (NP (NP (NNS tumors)) (PP (IN with) (NP (NN MYCN) (NN amplification))))))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (JJ MYCN-regulated) (NNS miRNAs)) (VP (VBP are) (ADJP (JJ able) (S (VP (TO to) (VP (VB modulate) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (DT the) (NN tumor) (NN suppressor) (NN DKK3))) (PP (IN in) (NP (NN neuroblastoma))))))))))))) (. .)))